Varian Medical Systems nails down an $87 million order to outfit the Maryland Proton Therapy Center with its ProBeam cancer treatment device.
ViewRay rescinds its planned $52 million initial public offering, saying it might float a private offering instead.
ViewRay yesterday became the latest medical device company to scrap an initial public offering, withdrawing a flotation that would have raised $52 million for its MRI-guided radiation therapy technology.
ViewRay reportedly postpones its planned initial public offering, which would have raised $52 million at the midpoint.
ViewRay postponed its initial public offering with which it planned to raise $52 million for its MRI-guided radiation therapy technology, Renaissance Capital reported.
Oakwood Village, Ohio-based ViewRay had planned to float 4 million shares at $12 to $14 apiece.
ViewRay sets the price range for its pending initial public offering, which would fetch $52 million at the midpoint.
ViewRay today set the terms for its pending initial public offering, saying it plans to float 4 million shares at $12 to $14 apiece.
At the midpoint of the range, the MRI-guided radiation therapy maker's IPO would fetch $52 million.
Varian Medical Systems says it plans to boost its footprint in Atlanta with a new facility there, adding 100 new jobs in the process.
ViewRay registers for an initial public offering worth up to $69 million for its MRIdian cancer detection and radiation treatment device.
ViewRay last week said it plans to raise up to $69 million in an initial public offering for its MRIdian system, which it bills as "the 1st and only MRI-guided radiation therapy system that images and treats cancer patients simultaneously."
Mevion Medical looks to go public with a $69 million stock offering as it gears up to scale its proton therapy device.
Mevion Medical registered for a $69 million initial public offering as it gears up to commercialize its proton therapy system.